Liminatus Pharma, Inc. Class A Common Stock
LIMN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $36 | $40 | $172 | $173 |
| - Cash | $1 | $0 | $5 | $0 |
| + Debt | $5 | $16 | $17 | $0 |
| Enterprise Value | $40 | $56 | $184 | $173 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$3 | -$1 | -$3 | $4 |
| % Margin | – | – | – | – |
| Net Income | -$3 | -$1 | -$3 | $4 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.4 | -0.15 | -0.082 | 0.13 |
| % Growth | -166.7% | -82.3% | -163.3% | – |
| Operating Cash Flow | -$3 | -$3 | -$1 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3 | -$3 | -$1 | -$1 |